| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S1040-8428(03)00075-1 |
| P698 | PubMed publication ID | 12900005 |
| P50 | author | Per-Uno Malmström | Q58469511 |
| P2860 | cites work | Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisati | Q77214850 |
| Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. The Kyushu University Urologi | Q77408655 | ||
| Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer | Q77449224 | ||
| A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder | Q77982540 | ||
| Thiotepa in the treatment of tumours of the bladder | Q79125292 | ||
| Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial | Q73773999 | ||
| Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors | Q73850895 | ||
| Pharmacologic effects of paclitaxel in human bladder tumors | Q74094307 | ||
| Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer | Q74107594 | ||
| Correlation between p53 over expression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer | Q74216164 | ||
| Prognostic markers of intravesical bacillus Calmette-Guérin therapy for multiple, high-grade, stage T1 bladder cancers | Q74226409 | ||
| Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study | Q74337157 | ||
| A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group | Q74471139 | ||
| Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer | Q74502885 | ||
| Activity of standard and investigational cytotoxic drugs in primary cultures of tumor cells from patients with kidney and urinary bladder carcinomas | Q28376685 | ||
| Thiotepa-induced myelosuppression: review of 670 bladder instillations. | Q33478108 | ||
| BCG immunotherapy of bladder cancer: 20 years on. | Q33640029 | ||
| Guidelines on bladder cancer | Q34695710 | ||
| Intravesical epodyl in the management of bladder tumors: combined experience of the Yorkshire Urological Cancer Research Group | Q34742620 | ||
| Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy | Q35765086 | ||
| Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer | Q36764367 | ||
| Role of P-glycoprotein in chemoresistant superficial bladder tumours. | Q38476170 | ||
| A Longitudinal Study of Patients with Superficial Bladder Carcinoma Successfully Treated with Weekly Intravesical Thio-TEPA | Q39672312 | ||
| BCG in perspective: advances in the treatment of superficial bladder cancer. | Q40525804 | ||
| Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. | Q40629967 | ||
| Intravesical chemotherapy and immunotherapy for superficial tumors Basic mechanism of action and future direction | Q40853260 | ||
| A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary ca | Q40887451 | ||
| Preparation of a conjugate of mitomycin C and anti-neural cell adhesion molecule monoclonal antibody for specific chemotherapy against biliary tract carcinoma | Q40988864 | ||
| Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer | Q41360899 | ||
| Intravesical chemotherapy: combination with dimethyl sulfoxide does not enhance cytotoxicity in vitro | Q41398927 | ||
| Treatment of superficial bladder cancer with intravesical chemotherapy | Q41564528 | ||
| Immunotherapy of bladder cancer | Q41564538 | ||
| The effect of pH on the in vitro colony forming ability of transitional cell carcinoma cells treated with various chemotherapeutic agents: implications for in vivo therapy | Q41640809 | ||
| Intravesical chemotherapy: in vitro studies on the relationship between dose and cytotoxicity | Q41767645 | ||
| Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study | Q42144921 | ||
| Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). | Q42200469 | ||
| Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa | Q42248822 | ||
| Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy | Q42556054 | ||
| Antineoplastic drug cytotoxicity in a human bladder cancer cell line: implications for intravesical chemotherapy | Q43509645 | ||
| Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. | Q43640423 | ||
| Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up | Q44426171 | ||
| Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer. | Q44492856 | ||
| Optimising mitomycin C activity during intravesical instillation | Q44508406 | ||
| Superficial bladder cancer: the role of interferon-alpha. | Q44708076 | ||
| Adjuvant Chemotherapy of Recurrent Superficial Transitional Cell Carcinoma: Results of a European Organization for Research on Treatment of Cancer Randomized Trial Comparing Intravesical Instillation of Thiotepa, Doxorubicin and Cisplatin | Q44749111 | ||
| Prognostic significance of DNA ploidy in Ta/Tl bladder cancer: A southwest oncology group study. | Q46042849 | ||
| A method to study drug concentration-depth profiles in tissues: mitomycin C in dog bladder wall. | Q52456966 | ||
| The site of recurrence of non-infiltrating bladder tumours. | Q53585948 | ||
| Intravesical chemotherapy: studies on the relationship between osmolality and cytotoxicity. | Q53800338 | ||
| Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor. | Q53849420 | ||
| Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients. | Q54516963 | ||
| Clinical Significance of Multi-Drug Resistance Associated Protein and P-Glycoprotein in Patients with Bladder Cancer | Q60310600 | ||
| Intravesical Thiotepa versus Mitomycin C in Patients with TA, T1 and TIS Transitional Cell Carcinoma of the Bladder: A Phase III Prospective Randomized Study | Q60355495 | ||
| Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients | Q67300379 | ||
| Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma | Q67520941 | ||
| Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin | Q67552732 | ||
| ThioTEPA pharmacokinetics during intravesical chemotherapy and the influence of Tween 80 | Q67653080 | ||
| Intravesical Chemotherapy (Mitomycin C) versus Immunotherapy (Bacillus Calmette-Guérin) in Superficial Bladder Cancer | Q67763282 | ||
| Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder | Q67921757 | ||
| Cultured human bladder tumors for pharmacodynamic studies | Q67982022 | ||
| Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder | Q68045536 | ||
| Mitomycin C in multiple superficial bladder tumors: short-term therapy, long-term results | Q68124707 | ||
| Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times | Q68135077 | ||
| Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial | Q68163318 | ||
| Dimethylsulfoxide enhances the absorption of chemotherapeutic drug instilled into the bladder | Q68178548 | ||
| Natural history and treatment of low and high risk superficial bladder tumors | Q68260027 | ||
| Antitumor Activity of Doxorubicin-Monoclonal Antibody Conjugate on Human Bladder Cancer | Q68453727 | ||
| A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer | Q68936844 | ||
| Metaphylactic effect of mitomycin C with and without hyaluronidase after transurethral resection of bladder cancer: randomized trial | Q69178342 | ||
| Conservative treatment of diffuse carcinoma in situ of the bladder with repeated courses of intravesical therapy | Q69224436 | ||
| Adverse reactions to the intravesical administration of doxorubicin hydrochloride: report of 6 cases | Q69574036 | ||
| The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer | Q69875558 | ||
| A controlled trial of single dose intravesical adriamycin in superficial bladder tumours | Q70201247 | ||
| Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Results of a controlled, prospective study in 58 patients | Q70256311 | ||
| Intravesical chemotherapy: combination with Tween 80 increases cytotoxicity in vitro | Q70329988 | ||
| Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group | Q70362732 | ||
| Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial | Q70428731 | ||
| Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa | Q70445702 | ||
| Absorption of doxorubicin-hydrochloride and mitomycin-C after instillation into noninfected and infected bladders of dogs | Q70471867 | ||
| A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group | Q70821756 | ||
| ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour | Q71006225 | ||
| Penetration of intravesical doxorubicin in human bladders | Q71032326 | ||
| Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction | Q71067351 | ||
| Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer | Q71083098 | ||
| The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up | Q71083101 | ||
| A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics | Q71263466 | ||
| Recurrences and progression of superficial bladder cancer following long-term intravesical prophylactic therapy with mitomycin C: 48-month follow-up | Q71454440 | ||
| Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group | Q71496158 | ||
| The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder | Q71538830 | ||
| Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone | Q71609647 | ||
| A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment | Q71764892 | ||
| Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures | Q71953483 | ||
| Toxic and therapeutic activity of 4'-epi-doxorubicin | Q72050761 | ||
| Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result | Q72641837 | ||
| Prophylactic chemotherapy with intravesical instillation of adriamycin and oral administration of 5-fluorouracil after surgery for superficial bladder cancer. The Japanese Urological Cancer Research Group for Adriamycin | Q72893467 | ||
| Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies | Q73074277 | ||
| Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation | Q73251731 | ||
| Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study | Q73354099 | ||
| Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study | Q73437870 | ||
| Bladder tissue pharmacokinetics of intravesical taxol | Q73516073 | ||
| P433 | issue | 2 | |
| P921 | main subject | bladder cancer | Q504775 |
| P304 | page(s) | 109-126 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Critical Reviews in Oncology Hematology | Q15724423 |
| P1476 | title | Intravesical therapy of superficial bladder cancer | |
| P478 | volume | 47 |
| Q24234614 | Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer |
| Q93184840 | Intravesical delivery of rapamycin via folate-modified liposomes dispersed in thermo-reversible hydrogel |
| Q37787341 | Intravesical drug delivery: Challenges, current status, opportunities and novel strategies |
| Q38930741 | In Vitro and Ex Vivo Permeability Studies of Paclitaxel and Doxorubicin From Drug-Eluting Biodegradable Ureteral Stents |
| Q44681270 | Long‐term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin‐C alone as adjuvant treatment for non‐muscle‐invasive bladder cancer (NMIBC) |
| Q55452723 | New Avenues for Nanoparticle-Related Therapies. |
| Q92757761 | Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer |
| Q82420310 | The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations |
| Q83197983 | [Hematogenous contact dermatitis after intravesicular instillation of mitomycin C] |
Search more.